Outcomes of Intermediate Risk Non–muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials

Study limitation reported by the research below: “The 60-month recurrence-free rate is based on a subset of patients with sufficient follow-up, as the median follow-up was only 34 months — long-term estimates carry uncertainty.”